TapewireFind a company

person · Reporting owner

Tepper Robert I

Disclosed activity across 17 companies

Tapewire entity
104809
SEC CIK
0001192595

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Allena Pharmaceuticals, Inc.ALNA · Entity 130904Director · 10% ownerJune 05, 2019June 07, 2019
Blueprint Medicines CorpBPMC · Entity 7732610% ownerFebruary 27, 2017February 28, 2017
CONSTELLATION PHARMACEUTICALS INCCNST · Entity 137050Director · 10% ownerJune 06, 2019June 10, 2019
Decibel Therapeutics, Inc.[DBTX] · Entity 10945810% ownerFebruary 11, 2021February 12, 2021
Jounce Therapeutics, Inc.JNCE · Entity 1575410% ownerNovember 12, 2021November 16, 2021
KALA BIO, Inc.KALA · Entity 7964DirectorJuly 25, 2017July 26, 2017
Nurix Therapeutics, Inc.NRIX · Entity 115610% ownerMay 06, 2021May 10, 2021
RHYTHM PHARMACEUTICALS, INC.RYTM · Entity 369310% ownerAugust 30, 2018September 04, 2018
Relay Therapeutics, Inc.RLAY · Entity 404410% ownerJanuary 12, 2021January 14, 2021
Revolution Medicines, Inc.RVMD · Entity 60610% ownerJune 08, 2022June 10, 2022

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Allena Pharmaceuticals, Inc.

Report date June 05, 2019 · Filed June 07, 2019

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.59 · Expires 2029-06-04Direct14,000 Reported balance After 2019-06-05 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2019-06-05 · Grant · Acquired 14,000 · Balance 14,000

F1: Stock option shall vest in full (i.e., in single installment) upon the earlier to occur of the first anniversary of the date of grant or the date of the next annual meeting of shareholders.

Filing footnotes · ownership attribution and instrument terms

F1: Stock option shall vest in full (i.e., in single installment) upon the earlier to occur of the first anniversary of the date of grant or the date of the next annual meeting of shareholders.

Blueprint Medicines Corp

Report date February 27, 2017 · Filed February 28, 2017

Jointly reported with Third Rock Ventures II, L.P., Third Rock Ventures GP II, L.P., TRV GP II, LLC, Levin Mark J, STARR KEVIN P

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect3,453,753 Reported balance After 2017-02-27 transaction · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · 2017-02-27 · Other · Disposed 1,000,000 · Balance 3,453,753

F1: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures II, L.P. ("TRV II"), TRV II distributed on February 27, 2017, for no consideration, 1,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP II, L.P. ("TRV GP II"), the general partner of TRV II, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP II distributed, for no consideration, the Shares it received in the distribution by TRV II to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F2: These shares are directly held by TRV II. The general partner of TRV II is TRV GP II. The general partner of TRV GP II is TRV GP II, LLC ("TRV GP II LLC"). The individual managers of TRV GP II LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Common StockSEC Table I · non-derivativeDirect141,240 Reported balance Holding disclosure · report date 2017-02-27 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 141,240

F3: These shares are directly held by Tepper.

Common StockSEC Table I · non-derivativeDirect141,244 Reported balance Holding disclosure · report date 2017-02-27 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 141,244

F4: These shares are directly held by Levin.

Common StockSEC Table I · non-derivativeDirect34,750 Reported balance Holding disclosure · report date 2017-02-27 · row 4 Holding and transaction disclosures are not merged.
1 source row

Row 4 · Balance 34,750

F5: These shares are directly held by Starr.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures II, L.P. ("TRV II"), TRV II distributed on February 27, 2017, for no consideration, 1,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP II, L.P. ("TRV GP II"), the general partner of TRV II, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP II distributed, for no consideration, the Shares it received in the distribution by TRV II to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F2: These shares are directly held by TRV II. The general partner of TRV II is TRV GP II. The general partner of TRV GP II is TRV GP II, LLC ("TRV GP II LLC"). The individual managers of TRV GP II LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F3: These shares are directly held by Tepper.

F4: These shares are directly held by Levin.

F5: These shares are directly held by Starr.

CONSTELLATION PHARMACEUTICALS INC

Report date June 06, 2019 · Filed June 10, 2019

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.12 · Expires 2029-06-05Direct13,171 Reported balance After 2019-06-06 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2019-06-06 · Grant · Acquired 13,171 · Balance 13,171

F1: This option was granted on June 6, 2019 and will vest as to all shares underlying the option on June 6, 2020, subject to continued service.

Filing footnotes · ownership attribution and instrument terms

F1: This option was granted on June 6, 2019 and will vest as to all shares underlying the option on June 6, 2020, subject to continued service.

Decibel Therapeutics, Inc.

Report date February 11, 2021 · Filed February 12, 2021

Jointly reported with Third Rock Ventures III, L.P., Third Rock Ventures GP III, L.P., TRV GP III, LLC, Levin Mark J, STARR KEVIN P

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect47,169 Reported balance Holding disclosure · report date 2021-02-11 · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · Balance 47,169

F1: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of these shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Series A Convertible Preferred StockSEC Table II · derivative / convertible securityDirectNot disclosed Reported balance Holding disclosure · report date 2021-02-11 · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · Balance Not disclosed

F2: The Series A Preferred Stock is convertible into common stock on a 15.529-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.

F1: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of these shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Series C Convertible Preferred StockSEC Table II · derivative / convertible securityDirectNot disclosed Reported balance Holding disclosure · report date 2021-02-11 · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · Balance Not disclosed

F3: The Series C Preferred Stock is convertible into common stock on a 12.6352-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date

F1: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of these shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Series D Convertible Preferred StockSEC Table II · derivative / convertible securityDirectNot disclosed Reported balance Holding disclosure · report date 2021-02-11 · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · Balance Not disclosed

F4: The Series D Preferred Stock is convertible into common stock on a 5.3-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.

F1: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of these shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Filing footnotes · ownership attribution and instrument terms

F1: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of these shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F2: The Series A Preferred Stock is convertible into common stock on a 15.529-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.

F3: The Series C Preferred Stock is convertible into common stock on a 12.6352-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date

F4: The Series D Preferred Stock is convertible into common stock on a 5.3-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.

Jounce Therapeutics, Inc.

Report date November 12, 2021 · Filed November 16, 2021

Jointly reported with Third Rock Ventures III, L.P., Third Rock Ventures GP III, L.P., TRV GP III, LLC, STARR KEVIN P, Levin Mark J

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect1,148,780 Reported balance After 2021-11-12 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2021-11-12 · Sale · Disposed 1,900,000 · Balance 1,148,780

F1: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.30 to $8.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F2: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Common StockSEC Table I · non-derivativeIndirectSee footnote2,697,829 Reported balance Holding disclosure · report date 2021-11-12 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 2,697,829

F3: These shares are directly held by Third Rock Ventures II, L.P. ("TRV II"). The general partner of TRV II is Third Rock Ventures GP II, L.P. ("TRV GP II"). The general partner of TRV GP II is TRV GP II, LLC ("TRV GP II LLC"). The individual managers of TRV GP II LLC are Levin, Starr and Tepper. Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Common StockSEC Table I · non-derivativeIndirectSee footnote284,344 Reported balance Holding disclosure · report date 2021-11-12 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 284,344

F4: The shares are directly held by Levin.

Common StockSEC Table I · non-derivativeIndirectSee footnote283,850 Reported balance Holding disclosure · report date 2021-11-12 · row 4 Holding and transaction disclosures are not merged.
1 source row

Row 4 · Balance 283,850

F5: The shares are directly held by Starr.

Common StockSEC Table I · non-derivativeIndirectSee footnote283,858 Reported balance Holding disclosure · report date 2021-11-12 · row 5 Holding and transaction disclosures are not merged.
1 source row

Row 5 · Balance 283,858

F6: The shares are directly held by Tepper.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.30 to $8.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F2: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F3: These shares are directly held by Third Rock Ventures II, L.P. ("TRV II"). The general partner of TRV II is Third Rock Ventures GP II, L.P. ("TRV GP II"). The general partner of TRV GP II is TRV GP II, LLC ("TRV GP II LLC"). The individual managers of TRV GP II LLC are Levin, Starr and Tepper. Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F4: The shares are directly held by Levin.

F5: The shares are directly held by Starr.

F6: The shares are directly held by Tepper.

KALA BIO, Inc.

Report date July 25, 2017 · Filed July 26, 2017

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectSee footnote.1,621,092 Reported balance After 2017-07-25 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 1 · 2017-07-25 · Conversion · Acquired 1,621,092 · Balance 1,621,092

F1: The Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock converted into Common Stock on a 5.2083-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F4: These shares are held by TRV. The general partner of TRV is TRV GP. The general partner of TRV GP is TRV GP LLC. The individual managers of TRV GP LLC are Levin, Starr and Tepper. Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Series Seed Preferred StockSEC Table II · derivative / convertible securityIndirectSee footnote.0 Reported balance After 2017-07-25 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2017-07-25 · Conversion · Disposed 3,677,374 · Balance 0

F1: The Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock converted into Common Stock on a 5.2083-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F3: These shares were held by Third Rock Ventures, L.P. ("TRV"). The general partner of TRV is Third Rock Ventures GP, L.P. ("TRV GP"). The general partner of TRV GP is TRV GP, LLC ("TRV GP LLC"). The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Series A Preferred StockSEC Table II · derivative / convertible securityIndirectSee footnote.0 Reported balance After 2017-07-25 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2017-07-25 · Conversion · Disposed 2,500,000 · Balance 0

F1: The Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock converted into Common Stock on a 5.2083-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F3: These shares were held by Third Rock Ventures, L.P. ("TRV"). The general partner of TRV is Third Rock Ventures GP, L.P. ("TRV GP"). The general partner of TRV GP is TRV GP, LLC ("TRV GP LLC"). The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Series B Preferred StockSEC Table II · derivative / convertible securityIndirectSee footnote.0 Reported balance After 2017-07-25 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2017-07-25 · Conversion · Disposed 2,265,764 · Balance 0

F1: The Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock converted into Common Stock on a 5.2083-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F3: These shares were held by Third Rock Ventures, L.P. ("TRV"). The general partner of TRV is Third Rock Ventures GP, L.P. ("TRV GP"). The general partner of TRV GP is TRV GP, LLC ("TRV GP LLC"). The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Series B Preferred Stock Warrant (right to buy)SEC Table II · derivative / convertible securityIndirectSee footnote.0 Reported balance After 2017-07-25 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2017-07-25 · Conversion · Disposed 173,611 · Balance 0

F2: The Series B Preferred Stock Warrant was exercisable for such shares of Preferred Stock at an exercise price of $1.44 per share. Upon the closing of the Issuer's initial public offering, the Warrant automatically became exercisable for 33,333 shares of Common Stock at an exercise price of $7.50 per share. The Warrant is exercisable at any time at the holder's election on or before April 16, 2021.

F3: These shares were held by Third Rock Ventures, L.P. ("TRV"). The general partner of TRV is Third Rock Ventures GP, L.P. ("TRV GP"). The general partner of TRV GP is TRV GP, LLC ("TRV GP LLC"). The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Common Stock Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.50IndirectSee footnote.33,333 Reported balance After 2017-07-25 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2017-07-25 · Conversion · Acquired 33,333 · Balance 33,333

F2: The Series B Preferred Stock Warrant was exercisable for such shares of Preferred Stock at an exercise price of $1.44 per share. Upon the closing of the Issuer's initial public offering, the Warrant automatically became exercisable for 33,333 shares of Common Stock at an exercise price of $7.50 per share. The Warrant is exercisable at any time at the holder's election on or before April 16, 2021.

F4: These shares are held by TRV. The general partner of TRV is TRV GP. The general partner of TRV GP is TRV GP LLC. The individual managers of TRV GP LLC are Levin, Starr and Tepper. Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Filing footnotes · ownership attribution and instrument terms

F1: The Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock converted into Common Stock on a 5.2083-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F2: The Series B Preferred Stock Warrant was exercisable for such shares of Preferred Stock at an exercise price of $1.44 per share. Upon the closing of the Issuer's initial public offering, the Warrant automatically became exercisable for 33,333 shares of Common Stock at an exercise price of $7.50 per share. The Warrant is exercisable at any time at the holder's election on or before April 16, 2021.

F3: These shares were held by Third Rock Ventures, L.P. ("TRV"). The general partner of TRV is Third Rock Ventures GP, L.P. ("TRV GP"). The general partner of TRV GP is TRV GP, LLC ("TRV GP LLC"). The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F4: These shares are held by TRV. The general partner of TRV is TRV GP. The general partner of TRV GP is TRV GP LLC. The individual managers of TRV GP LLC are Levin, Starr and Tepper. Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Nurix Therapeutics, Inc.

Report date May 06, 2021 · Filed May 10, 2021

Jointly reported with Third Rock Ventures III, L.P., Third Rock Ventures GP III, L.P., TRV GP III, LLC, STARR KEVIN P, Levin Mark J

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect3,422,549 Reported balance After 2021-05-06 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2021-05-06 · Other · Disposed 1,085,784 · Balance 3,422,549

F1: Pursuant to a 10b5-1 trading plan adopted on October 29, 2020 by Third Rock Ventures III, L.P. ("TRV III"), TRV III distributed for no consideration, 1,085,784 shares of Common Stock of the Issuer (the "Shares") on May 6, 2021 to its limited partners and to Third Rock Ventures GP III, L.P. ("TRV GP III"), the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F2: These shares are directly held by TRV III. The general partner of TRV III is TRV GP III. The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Common StockSEC Table I · non-derivativeIndirectSee footnote78,118 Reported balance Holding disclosure · report date 2021-05-06 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 78,118

F3: The shares are directly held by Levin. Includes Shares received in the distributions described in footnote (1) above.

Common StockSEC Table I · non-derivativeIndirectSee footnote8,677 Reported balance Holding disclosure · report date 2021-05-06 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 8,677

F4: The shares are directly held by Levin Family 2014 Irrevocable Trust. Includes Shares received in the distributions described in footnote (1) above.

Common StockSEC Table I · non-derivativeIndirectSee footnote86,798 Reported balance Holding disclosure · report date 2021-05-06 · row 4 Holding and transaction disclosures are not merged.
1 source row

Row 4 · Balance 86,798

F5: The shares are directly held by Starr. Includes Shares received in the distributions described in footnote (1) above.

Common StockSEC Table I · non-derivativeIndirectSee footnote86,799 Reported balance Holding disclosure · report date 2021-05-06 · row 5 Holding and transaction disclosures are not merged.
1 source row

Row 5 · Balance 86,799

F6: The shares are directly held by Tepper. Includes Shares received in the distributions described in footnote (1) above.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to a 10b5-1 trading plan adopted on October 29, 2020 by Third Rock Ventures III, L.P. ("TRV III"), TRV III distributed for no consideration, 1,085,784 shares of Common Stock of the Issuer (the "Shares") on May 6, 2021 to its limited partners and to Third Rock Ventures GP III, L.P. ("TRV GP III"), the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F2: These shares are directly held by TRV III. The general partner of TRV III is TRV GP III. The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F3: The shares are directly held by Levin. Includes Shares received in the distributions described in footnote (1) above.

F4: The shares are directly held by Levin Family 2014 Irrevocable Trust. Includes Shares received in the distributions described in footnote (1) above.

F5: The shares are directly held by Starr. Includes Shares received in the distributions described in footnote (1) above.

F6: The shares are directly held by Tepper. Includes Shares received in the distributions described in footnote (1) above.

RHYTHM PHARMACEUTICALS, INC.

Report date August 30, 2018 · Filed September 04, 2018

Jointly reported with THIRD ROCK VENTURES LP, Third Rock Ventures GP, L.P., TRV GP, LLC, STARR KEVIN P, Levin Mark J

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect2,981,437 Reported balance After 2018-08-30 transaction · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · 2018-08-30 · Other · Disposed 1,000,000 · Balance 2,981,437

F1: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures, L.P. ("TRV"), Third Rock Ventures GP, L.P. ("TRV GP") and TRV GP, LLC ("TRV GP LLC"), TRV distributed on August 30, 2018, for no consideration, 1,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to TRV GP, the general partner of TRV, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP distributed, for no consideration, the Shares it received in the distribution by TRV to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F2: These shares are directly held by TRV. The general partner of TRV is TRV GP. The general partner of TRV GP is TRV GP LLC. The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Common StockSEC Table I · non-derivativeDirect99,105 Reported balance Holding disclosure · report date 2018-08-30 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 99,105

F3: These shares are directly held by Starr. Includes Shares received in the distributions described in footnote (1) above.

Common StockSEC Table I · non-derivativeDirect99,105 Reported balance Holding disclosure · report date 2018-08-30 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 99,105

F4: These shares are directly held by Tepper. Includes Shares received in the distributions described in footnote (1) above.

Common StockSEC Table I · non-derivativeDirect99,105 Reported balance Holding disclosure · report date 2018-08-30 · row 4 Holding and transaction disclosures are not merged.
1 source row

Row 4 · Balance 99,105

F5: These shares are directly held by Levin. Includes Shares received in the distributions described in footnote (1) above.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures, L.P. ("TRV"), Third Rock Ventures GP, L.P. ("TRV GP") and TRV GP, LLC ("TRV GP LLC"), TRV distributed on August 30, 2018, for no consideration, 1,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to TRV GP, the general partner of TRV, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP distributed, for no consideration, the Shares it received in the distribution by TRV to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F2: These shares are directly held by TRV. The general partner of TRV is TRV GP. The general partner of TRV GP is TRV GP LLC. The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F3: These shares are directly held by Starr. Includes Shares received in the distributions described in footnote (1) above.

F4: These shares are directly held by Tepper. Includes Shares received in the distributions described in footnote (1) above.

F5: These shares are directly held by Levin. Includes Shares received in the distributions described in footnote (1) above.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect7,739,918 Last balance in matching sequence After 2021-01-13 transaction · row 6 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
6 source rows

Row 1 · 2021-01-12 · Sale · Disposed 1,500,000 · Balance 9,051,115

F1: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F14: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Row 2 · 2021-01-13 · Sale · Disposed 1,247,873 · Balance 7,803,242

F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2).

F1: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F14: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Row 3 · 2021-01-13 · Sale · Disposed 8,727 · Balance 7,794,515

F3: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3).

F1: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F14: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Row 4 · 2021-01-13 · Sale · Disposed 42,860 · Balance 7,751,655

F4: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4).

F1: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F14: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Row 5 · 2021-01-13 · Sale · Disposed 4,325 · Balance 7,747,330

F5: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.04 to $44.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5).

F1: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F14: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Row 6 · 2021-01-13 · Sale · Disposed 7,412 · Balance 7,739,918

F6: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.03 to $44.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (6).

F1: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F14: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Common StockSEC Table I · non-derivativeIndirectSee Footnotes0 Last balance in matching sequence After 2021-01-14 transaction · row 12 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
6 source rows

Row 7 · 2021-01-13 · Sale · Disposed 805,050 · Balance 2,006,147

F7: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (7).

F13: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of the reporting persons, except for TRV IV, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F14: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Row 8 · 2021-01-13 · Sale · Disposed 5,630 · Balance 2,000,517

F8: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (8).

F13: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of the reporting persons, except for TRV IV, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F14: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Row 9 · 2021-01-13 · Sale · Disposed 27,650 · Balance 1,972,867

F9: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (9).

F13: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of the reporting persons, except for TRV IV, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F14: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Row 10 · 2021-01-13 · Sale · Disposed 2,791 · Balance 1,970,076

F10: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.04 to $44.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (10).

F13: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of the reporting persons, except for TRV IV, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F14: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Row 11 · 2021-01-13 · Sale · Disposed 4,782 · Balance 1,965,294

F11: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.03 to $44.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (11).

F13: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of the reporting persons, except for TRV IV, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F14: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Row 12 · 2021-01-14 · Sale · Disposed 1,965,294 · Balance 0

F12: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (12).

F13: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of the reporting persons, except for TRV IV, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F14: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Filing footnotes · ownership attribution and instrument terms

F1: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2).

F3: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3).

F4: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4).

F5: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.04 to $44.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5).

F6: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.03 to $44.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (6).

F7: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (7).

F8: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (8).

F9: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (9).

F10: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.04 to $44.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (10).

F11: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.03 to $44.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (11).

F12: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (12).

F13: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of the reporting persons, except for TRV IV, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F14: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Revolution Medicines, Inc.

Report date June 08, 2022 · Filed June 10, 2022

Jointly reported with Third Rock Ventures III, L.P., Third Rock Ventures GP III, L.P., TRV GP III, LLC

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect5,104,130 Reported balance After 2022-06-08 transaction · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · 2022-06-08 · Sale · Disposed 419,901 · Balance 5,104,130

F1: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.25 to $20.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1).

F2: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual manager of TRV GP III LLC is Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares

Common StockSEC Table I · non-derivativeDirect129,258 Reported balance Holding disclosure · report date 2022-06-08 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 129,258

F4: The shares are directly held by Tepper.

Common StockSEC Table I · non-derivativeIndirectSee footnote0 Reported balance Holding disclosure · report date 2022-06-08 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 0

F3: Third Rock Ventures IV, L.P. ("TRV IV") directly holds 1,419,900 shares of Common Stock of the Issuer. The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of the reporting persons and TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.25 to $20.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1).

F2: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual manager of TRV GP III LLC is Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares

F3: Third Rock Ventures IV, L.P. ("TRV IV") directly holds 1,419,900 shares of Common Stock of the Issuer. The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of the reporting persons and TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.

F4: The shares are directly held by Tepper.

Past disclosures · reporting ended (7)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

CytomX Therapeutics, Inc.

Report date October 18, 2017 · Filed October 19, 2017

Jointly reported with THIRD ROCK VENTURES LP, Third Rock Ventures GP, L.P., TRV GP, LLC, Levin Mark J, STARR KEVIN P

Section 16 reporting ended · disclosed 2017-10-19. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect3,320,348 Reported balance After 2017-10-18 transaction · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · 2017-10-18 · Other · Disposed 1,000,000 · Balance 3,320,348

F1: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures, L.P. ("TRV"), TRV distributed on October 18, 2017, for no consideration, 1,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP, L.P. ("TRV GP"), the general partner of TRV, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP distributed, for no consideration, the Shares it received in the distribution by TRV to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F2: These shares are directly held by TRV. The general partner of TRV is TRV GP. The general partner of TRV GP is TRV GP, LLC ("TRV GP LLC"). The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Common StockSEC Table I · non-derivativeDirect116,927 Reported balance Holding disclosure · report date 2017-10-18 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 116,927

F3: These shares are directly held by Starr. Includes Shares received in the distributions described in footnote (1) above.

Common StockSEC Table I · non-derivativeDirect145,286 Reported balance Holding disclosure · report date 2017-10-18 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 145,286

F4: These shares are directly held by Levin. Includes Shares received in the distributions described in footnote (1) above.

Common StockSEC Table I · non-derivativeDirect85,509 Reported balance Holding disclosure · report date 2017-10-18 · row 4 Holding and transaction disclosures are not merged.
1 source row

Row 4 · Balance 85,509

F5: These shares are directly held by Tepper. Includes Shares received in the distributions described in footnote (1) above.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures, L.P. ("TRV"), TRV distributed on October 18, 2017, for no consideration, 1,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP, L.P. ("TRV GP"), the general partner of TRV, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP distributed, for no consideration, the Shares it received in the distribution by TRV to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F2: These shares are directly held by TRV. The general partner of TRV is TRV GP. The general partner of TRV GP is TRV GP, LLC ("TRV GP LLC"). The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F3: These shares are directly held by Starr. Includes Shares received in the distributions described in footnote (1) above.

F4: These shares are directly held by Levin. Includes Shares received in the distributions described in footnote (1) above.

F5: These shares are directly held by Tepper. Includes Shares received in the distributions described in footnote (1) above.

Fulcrum Therapeutics, Inc.

Report date December 13, 2022 · Filed December 15, 2022

Jointly reported with Third Rock Ventures III, L.P., Third Rock Ventures GP III, L.P., TRV GP III, LLC

Section 16 reporting ended · disclosed 2022-12-15. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect1,962,202 Reported balance After 2022-12-13 transaction · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · 2022-12-13 · Other · Disposed 2,000,000 · Balance 1,962,202

F1: On December 13, 2022, Third Rock Ventures III, L.P. ("TRV III") distributed for no consideration, 2,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP III, L.P. ("TRV GP III"), the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F2: These shares are directly held by TRV III. The general partner of TRV III is TRV GP III. The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual manager of TRV GP III LLC is Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Common StockSEC Table I · non-derivativeDirect156,189 Reported balance Holding disclosure · report date 2022-12-13 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 156,189

F4: The shares are directly held by Tepper. Includes Shares received in the distributions described in footnote (1) above.

Common StockSEC Table I · non-derivativeIndirectSee footnote2,343,154 Reported balance Holding disclosure · report date 2022-12-13 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 2,343,154

F3: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares. Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Filing footnotes · ownership attribution and instrument terms

F1: On December 13, 2022, Third Rock Ventures III, L.P. ("TRV III") distributed for no consideration, 2,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP III, L.P. ("TRV GP III"), the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F2: These shares are directly held by TRV III. The general partner of TRV III is TRV GP III. The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual manager of TRV GP III LLC is Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F3: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares. Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

F4: The shares are directly held by Tepper. Includes Shares received in the distributions described in footnote (1) above.

Global Blood Therapeutics, Inc.

Report date June 14, 2017 · Filed June 16, 2017

Jointly reported with Third Rock Ventures II, L.P., Third Rock Ventures GP II, L.P., TRV GP II, LLC, Levin Mark J, STARR KEVIN P

Section 16 reporting ended · disclosed 2017-06-16. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect2,475,191 Reported balance After 2017-06-14 transaction · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · 2017-06-14 · Other · Disposed 1,000,000 · Balance 2,475,191

F1: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures II, L.P. ("TRV II"), Third Rock Ventures GP II, L.P. ("TRV GP II") and TRV GP II, LLC ("TRV GP II LLC"), TRV II distributed on June 14, 2017, for no consideration, 1,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to TRV GP II, the general partner of TRV II, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP II distributed, for no consideration, the Shares it received in the distribution by TRV II to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F2: These shares are directly held by TRV II. The general partner of TRV II is TRV GP II. The general partner of TRV GP II is TRV GP II LLC. The individual managers of TRV GP II LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Common StockSEC Table I · non-derivativeDirect212,204 Reported balance Holding disclosure · report date 2017-06-14 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 212,204

F3: These shares are directly held by Levin. Includes shares received in the distributions described in footnote (1) above.

F4: In addition to the reported shares, Third Rock Ventures III, L.P. ("TRV III") directly holds 285,713 shares of Common Stock of the Issuer. The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Levin, Starr and Tepper. Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Common StockSEC Table I · non-derivativeDirect200,249 Reported balance Holding disclosure · report date 2017-06-14 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 200,249

F5: These shares are directly held by Starr. Includes Shares received in the distributions described in footnote (1) above.

F4: In addition to the reported shares, Third Rock Ventures III, L.P. ("TRV III") directly holds 285,713 shares of Common Stock of the Issuer. The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Levin, Starr and Tepper. Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Common StockSEC Table I · non-derivativeDirect277,980 Reported balance Holding disclosure · report date 2017-06-14 · row 4 Holding and transaction disclosures are not merged.
1 source row

Row 4 · Balance 277,980

F6: These shares are directly held by Tepper. Includes Shares received in the distributions described in footnote (1) above.

F4: In addition to the reported shares, Third Rock Ventures III, L.P. ("TRV III") directly holds 285,713 shares of Common Stock of the Issuer. The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Levin, Starr and Tepper. Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures II, L.P. ("TRV II"), Third Rock Ventures GP II, L.P. ("TRV GP II") and TRV GP II, LLC ("TRV GP II LLC"), TRV II distributed on June 14, 2017, for no consideration, 1,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to TRV GP II, the general partner of TRV II, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP II distributed, for no consideration, the Shares it received in the distribution by TRV II to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F2: These shares are directly held by TRV II. The general partner of TRV II is TRV GP II. The general partner of TRV GP II is TRV GP II LLC. The individual managers of TRV GP II LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F3: These shares are directly held by Levin. Includes shares received in the distributions described in footnote (1) above.

F4: In addition to the reported shares, Third Rock Ventures III, L.P. ("TRV III") directly holds 285,713 shares of Common Stock of the Issuer. The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Levin, Starr and Tepper. Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F5: These shares are directly held by Starr. Includes Shares received in the distributions described in footnote (1) above.

F6: These shares are directly held by Tepper. Includes Shares received in the distributions described in footnote (1) above.

MyoKardia, Inc.

Report date March 07, 2018 · Filed March 07, 2018

Jointly reported with Third Rock Ventures II, L.P., Third Rock Ventures GP II, L.P., TRV GP II, LLC, Levin Mark J

Section 16 reporting ended · disclosed 2018-03-07. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect885,104 Reported balance After 2018-03-07 transaction · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · 2018-03-07 · Other · Disposed 2,000,000 · Balance 885,104

F1: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures II, L.P. ("TRV II"), Third Rock Ventures GP II, L.P. ("TRV GP II") and TRV GP II, LLC ("TRV GP II LLC"), TRV II distributed on March 7, 2018, for no consideration, 2,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to TRV GP II, the general partner of TRV II, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP II distributed, for no consideration, the Shares it received in the distribution by TRV II to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F2: These shares are directly held by TRV II. The general partner of TRV II is TRV GP II. The general partner of TRV GP II is TRV GP II LLC. The individual managers of TRV GP II LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Common StockSEC Table I · non-derivativeDirect265,057 Reported balance Holding disclosure · report date 2018-03-07 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 265,057

F3: Third Rock Ventures III, L.P. ("TRV III") directly holds 680,272 shares of Common Stock of the Issuer. The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Levin, Starr and Tepper. Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F4: The shares are directly held by Levin. Includes Shares received in the distributions described in footnote (1) above.

Common StockSEC Table I · non-derivativeDirect280,057 Reported balance Holding disclosure · report date 2018-03-07 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 280,057

F3: Third Rock Ventures III, L.P. ("TRV III") directly holds 680,272 shares of Common Stock of the Issuer. The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Levin, Starr and Tepper. Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F5: The shares are directly held by Tepper. Includes Shares received in the distributions described in footnote (1) above.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures II, L.P. ("TRV II"), Third Rock Ventures GP II, L.P. ("TRV GP II") and TRV GP II, LLC ("TRV GP II LLC"), TRV II distributed on March 7, 2018, for no consideration, 2,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to TRV GP II, the general partner of TRV II, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP II distributed, for no consideration, the Shares it received in the distribution by TRV II to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F2: These shares are directly held by TRV II. The general partner of TRV II is TRV GP II. The general partner of TRV GP II is TRV GP II LLC. The individual managers of TRV GP II LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F3: Third Rock Ventures III, L.P. ("TRV III") directly holds 680,272 shares of Common Stock of the Issuer. The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Levin, Starr and Tepper. Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F4: The shares are directly held by Levin. Includes Shares received in the distributions described in footnote (1) above.

F5: The shares are directly held by Tepper. Includes Shares received in the distributions described in footnote (1) above.

Neon Therapeutics, Inc.

Report date May 06, 2020 · Filed May 06, 2020

Section 16 reporting ended · disclosed 2020-05-06. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectSee footnote0 Reported balance After 2020-05-06 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 1 · 2020-05-06 · Disposition to issuer · Disposed 9,741,636 · Balance 0

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 15, 2020, by and among the Issuer, BioNTech SE ("BioNTech"), and Endor Lights, Inc. a direct wholly owned subsidiary of BioNTech ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of May 6, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive 0.063 (the "Exchange Ratio") of American Depositary Shares of BioNTech ("BioNTech ADS") plus the right, if any, to receive cash in lieu of fractional shares of BioNTech ADSs into which such Shares would have been converted.

F2: These Shares were directly held by TRV III. The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the Shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such Shares.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00Direct0 Reported balance After 2020-05-06 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2020-05-06 · Disposition to issuer · Disposed 14,000 · Balance 0

F3: Pursuant to the Merger Agreement, at the Effective Time, these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the "Cash Merger Consideration").

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.64Direct0 Reported balance After 2020-05-06 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2020-05-06 · Disposition to issuer · Disposed 18,500 · Balance 0

F3: Pursuant to the Merger Agreement, at the Effective Time, these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the "Cash Merger Consideration").

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 15, 2020, by and among the Issuer, BioNTech SE ("BioNTech"), and Endor Lights, Inc. a direct wholly owned subsidiary of BioNTech ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of May 6, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive 0.063 (the "Exchange Ratio") of American Depositary Shares of BioNTech ("BioNTech ADS") plus the right, if any, to receive cash in lieu of fractional shares of BioNTech ADSs into which such Shares would have been converted.

F2: These Shares were directly held by TRV III. The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the Shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such Shares.

F3: Pursuant to the Merger Agreement, at the Effective Time, these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the "Cash Merger Consideration").

PLIANT THERAPEUTICS, INC.

Report date November 29, 2022 · Filed December 01, 2022

Jointly reported with Third Rock Ventures III, L.P., Third Rock Ventures GP III, L.P., TRV GP III, LLC

Section 16 reporting ended · disclosed 2022-12-01. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect1,839,160 Reported balance After 2022-11-29 transaction · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · 2022-11-29 · Other · Disposed 2,000,000 · Balance 1,839,160

F1: On November 29, 2022, Third Rock Ventures III, L.P. ("TRV III") distributed for no consideration, 2,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP III, L.P. ("TRV GP III"), the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F2: These shares are directly held by TRV III. The general partner of TRV III is TRV GP III. The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual manager of TRV GP III LLC is Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Common StockSEC Table I · non-derivativeDirect229,504 Reported balance Holding disclosure · report date 2022-11-29 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 229,504

F4: The shares are directly held by Tepper. Includes Shares received in the distributions described in footnote (1) above.

Common StockSEC Table I · non-derivativeIndirectSee footnote2,132,867 Reported balance Holding disclosure · report date 2022-11-29 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 2,132,867

F3: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares. Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

Filing footnotes · ownership attribution and instrument terms

F1: On November 29, 2022, Third Rock Ventures III, L.P. ("TRV III") distributed for no consideration, 2,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP III, L.P. ("TRV GP III"), the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F2: These shares are directly held by TRV III. The general partner of TRV III is TRV GP III. The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual manager of TRV GP III LLC is Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F3: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares. Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.

F4: The shares are directly held by Tepper. Includes Shares received in the distributions described in footnote (1) above.

Voyager Therapeutics, Inc.

Report date February 02, 2023 · Filed February 06, 2023

Jointly reported with Third Rock Ventures III, L.P., Third Rock Ventures GP III, L.P., TRV GP III, LLC

Section 16 reporting ended · disclosed 2023-02-06. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect3,185,291 Reported balance After 2023-02-02 transaction · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · 2023-02-02 · Other · Disposed 1,500,000 · Balance 3,185,291

F1: On February 2, 2023, Third Rock Ventures III, L.P. ("TRV III") distributed, for no consideration, 1,500,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP III, L.P. ("TRV GP III"), the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F2: These shares are directly held by TRV III. The general partner of TRV III is TRV GP III. The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual manager of TRV GP III LLC is Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Common StockSEC Table I · non-derivativeDirect86,265 Reported balance Holding disclosure · report date 2023-02-02 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 86,265

F3: The shares are directly held by Tepper. Includes Shares received in the distributions described in footnote (1) above.

Filing footnotes · ownership attribution and instrument terms

F1: On February 2, 2023, Third Rock Ventures III, L.P. ("TRV III") distributed, for no consideration, 1,500,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP III, L.P. ("TRV GP III"), the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F2: These shares are directly held by TRV III. The general partner of TRV III is TRV GP III. The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual manager of TRV GP III LLC is Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F3: The shares are directly held by Tepper. Includes Shares received in the distributions described in footnote (1) above.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
June 29, 2018 Filed Jul 3, 2018 16:29 UTC Neon Therapeutics, Inc. NTGN · Entity 149433 ConversionSeries A Preferred Stock · Derivative 0 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-18-043854 · a4.xml · derivative · entry 3

TEPPER ROBERT I · CIK 0001192595 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 0 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: All series of Preferred Stock automatically converted into the Issuer's Common Stock on a 5-for-1 basis upon the closing of the Issuer's initial public offering on June 29, 2018 and had no expiration date.

F1 · shares: Third Rock Ventures III, L.P. ("TRV III") received 8,999,999 shares of Common Stock of the Issuer upon conversion of 45,000,000 shares of Series A Preferred Stock in connection with the closing of the Issuer's initial public offering.

F3 · price: All series of Preferred Stock automatically converted into the Issuer's Common Stock on a 5-for-1 basis upon the closing of the Issuer's initial public offering on June 29, 2018 and had no expiration date.

F3 · derivative.exercise_date: All series of Preferred Stock automatically converted into the Issuer's Common Stock on a 5-for-1 basis upon the closing of the Issuer's initial public offering on June 29, 2018 and had no expiration date.

F3 · derivative.expiration_date: All series of Preferred Stock automatically converted into the Issuer's Common Stock on a 5-for-1 basis upon the closing of the Issuer's initial public offering on June 29, 2018 and had no expiration date.

F1 · derivative.underlying_shares: Third Rock Ventures III, L.P. ("TRV III") received 8,999,999 shares of Common Stock of the Issuer upon conversion of 45,000,000 shares of Series A Preferred Stock in connection with the closing of the Issuer's initial public offering.

F5 · ownership.nature: These shares are directly held by TRV III. The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
June 29, 2018 Filed Jul 3, 2018 16:29 UTC Neon Therapeutics, Inc. NTGN · Entity 149433 ConversionCommon Stock 0 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-18-043854 · a4.xml · nonDerivative · entry 2

TEPPER ROBERT I · CIK 0001192595 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · shares: TRV III received 341,637 shares of Common Stock of the Issuer upon conversion of 1,708,185 shares of Series B Preferred Stock in connection with the closing of the Issuer's initial public offering.

F3 · price: All series of Preferred Stock automatically converted into the Issuer's Common Stock on a 5-for-1 basis upon the closing of the Issuer's initial public offering on June 29, 2018 and had no expiration date.

F6 · balance_after: After the above transaction, TRV III owned 9,741,636 shares of Common Stock of the Issuer.

F5 · ownership.nature: These shares are directly held by TRV III. The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
June 29, 2018 Filed Jul 3, 2018 16:29 UTC Neon Therapeutics, Inc. NTGN · Entity 149433 ConversionCommon Stock 0 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-18-043854 · a4.xml · nonDerivative · entry 1

TEPPER ROBERT I · CIK 0001192595 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Third Rock Ventures III, L.P. ("TRV III") received 8,999,999 shares of Common Stock of the Issuer upon conversion of 45,000,000 shares of Series A Preferred Stock in connection with the closing of the Issuer's initial public offering.

F3 · price: All series of Preferred Stock automatically converted into the Issuer's Common Stock on a 5-for-1 basis upon the closing of the Issuer's initial public offering on June 29, 2018 and had no expiration date.

F4 · balance_after: After the above transaction, TRV III owned 9,399,999 shares of Common Stock of the Issuer.

F5 · ownership.nature: These shares are directly held by TRV III. The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
June 20, 2018 Filed Jun 21, 2018 20:05 UTC Voyager Therapeutics, Inc. VYGR · Entity 6271 OtherCommon Stock 1,500,000 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-18-017587 · doc4.xml · nonDerivative · entry 1

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,891,176

F1 · kind: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures III, L.P. ("TRV III"), Third Rock Ventures GP III, L.P. ("TRV GP III") and TRV GP III, LLC ("TRV GP III LLC"), TRV III distributed on June 20, 2018, for no consideration, 1,500,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to TRV GP III, the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F1 · price: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures III, L.P. ("TRV III"), Third Rock Ventures GP III, L.P. ("TRV GP III") and TRV GP III, LLC ("TRV GP III LLC"), TRV III distributed on June 20, 2018, for no consideration, 1,500,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to TRV GP III, the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F2 · ownership.direct: These shares are directly held by TRV III. The general partner of TRV III is TRV GP III. The general partner of TRV GP III is TRV GP III LLC. The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
June 19, 2018 Filed Jun 21, 2018 17:13 UTC Jounce Therapeutics, Inc. JNCE · Entity 15754 GrantStock Option (Right to Buy) · Derivative 13,550 $0.00 Strike: $7.92 $0.00
Disclosure

SEC source: 0001640455-18-000081 · wf-form4_152961560410969.xml · derivative · entry 1

TEPPER ROBERT I · CIK 0001192595 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,550

Underlying: Common Stock · 13,550 shares

Expires 2028-06-19

F1 · derivative.exercise_date: The option will vest in equal quarterly installments during the four quarters following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors.

Read SEC document
June 08, 2018 Filed Jun 12, 2018 16:19 UTC Allena Pharmaceuticals, Inc. ALNA · Entity 130904 GrantStock Option (Right to Buy) · Derivative 10,182 $0.00 Strike: $13.52 $0.00
Disclosure

SEC source: 0001209191-18-037229 · doc4.xml · derivative · entry 1

TEPPER ROBERT I · CIK 0001192595 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,182

Underlying: Common Stock · 10,182 shares

Expires 2028-06-07

F1 · derivative.exercise_date: Stock option shall vest in full (i.e., in single installment) upon the earlier to occur of the first anniversary of the date of grant or the date of the next annual meeting of shareholders.

Read SEC document
March 07, 2018 Filed Mar 7, 2018 16:00 UTC MyoKardia, Inc. MYOK · Entity 145206 OtherCommon Stock 2,000,000 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-18-006627 · doc4.xml · nonDerivative · entry 1

Third Rock Ventures II, L.P. · CIK 0001488495 · 10% owner

Third Rock Ventures GP II, L.P. · CIK 0001614061 · 10% owner

TRV GP II, LLC · CIK 0001614073 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 885,104

F1 · kind: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures II, L.P. ("TRV II"), Third Rock Ventures GP II, L.P. ("TRV GP II") and TRV GP II, LLC ("TRV GP II LLC"), TRV II distributed on March 7, 2018, for no consideration, 2,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to TRV GP II, the general partner of TRV II, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP II distributed, for no consideration, the Shares it received in the distribution by TRV II to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F1 · price: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures II, L.P. ("TRV II"), Third Rock Ventures GP II, L.P. ("TRV GP II") and TRV GP II, LLC ("TRV GP II LLC"), TRV II distributed on March 7, 2018, for no consideration, 2,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to TRV GP II, the general partner of TRV II, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP II distributed, for no consideration, the Shares it received in the distribution by TRV II to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F2 · ownership.direct: These shares are directly held by TRV II. The general partner of TRV II is TRV GP II. The general partner of TRV GP II is TRV GP II LLC. The individual managers of TRV GP II LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
January 03, 2018 Filed Jan 5, 2018 16:30 UTC MyoKardia, Inc. MYOK · Entity 145206 SaleCommon Stock 816,326 $42.00 $34,285,773.63
Disclosure

SEC source: 0000899243-18-000584 · doc4.xml · nonDerivative · entry 1

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 680,272

F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1).

F2 · ownership.direct: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
December 06, 2017 Filed Dec 8, 2017 16:30 UTC MyoKardia, Inc. MYOK · Entity 145206 OtherCommon Stock 2,000,000 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-17-028251 · doc4.xml · nonDerivative · entry 1

Third Rock Ventures II, L.P. · CIK 0001488495 · 10% owner

Third Rock Ventures GP II, L.P. · CIK 0001614061 · 10% owner

TRV GP II, LLC · CIK 0001614073 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,885,104

F1 · kind: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures II, L.P. ("TRV II"), Third Rock Ventures GP II, L.P. ("TRV GP II") and TRV GP II, LLC ("TRV GP II LLC"), TRV II distributed on December 6, 2017, for no consideration, 2,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to TRV GP II, the general partner of TRV II, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP II distributed, for no consideration, the Shares it received in the distribution by TRV II to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F1 · price: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures II, L.P. ("TRV II"), Third Rock Ventures GP II, L.P. ("TRV GP II") and TRV GP II, LLC ("TRV GP II LLC"), TRV II distributed on December 6, 2017, for no consideration, 2,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to TRV GP II, the general partner of TRV II, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP II distributed, for no consideration, the Shares it received in the distribution by TRV II to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F2 · ownership.direct: These shares are directly held by TRV II. The general partner of TRV II is TRV GP II. The general partner of TRV GP II is TRV GP II LLC. The individual managers of TRV GP II LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
November 06, 2017 Filed Nov 6, 2017 19:04 UTC Allena Pharmaceuticals, Inc. ALNA · Entity 130904 ConversionSeries B Preferred Stock · Derivative 4,629,630 $0.00 $0.00
Disclosure

SEC source: 0000899243-17-025454 · doc4.xml · derivative · entry 4

TEPPER ROBERT I · CIK 0001192595 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,109,159 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: The Series A Preferred Stock and Series B Preferred Stock converted into Common Stock on a 4.174-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F2 · derivative.exercise_date: The Series A Preferred Stock and Series B Preferred Stock converted into Common Stock on a 4.174-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F2 · derivative.expiration_date: The Series A Preferred Stock and Series B Preferred Stock converted into Common Stock on a 4.174-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F3 · ownership.direct: These shares are directly held by TRV II. The general partner of TRV II is Third Rock Ventures GP II, L.P. ("TRV GP II"). The general partner of TRV GP II is TRV GP II, LLC ("TRV GP II LLC"). The individual managers of TRV GP II LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of these shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
November 06, 2017 Filed Nov 6, 2017 19:04 UTC Allena Pharmaceuticals, Inc. ALNA · Entity 130904 ConversionSeries A Preferred Stock · Derivative 6,122,448 $0.00 $0.00
Disclosure

SEC source: 0000899243-17-025454 · doc4.xml · derivative · entry 3

TEPPER ROBERT I · CIK 0001192595 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,466,805 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: The Series A Preferred Stock and Series B Preferred Stock converted into Common Stock on a 4.174-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F2 · derivative.exercise_date: The Series A Preferred Stock and Series B Preferred Stock converted into Common Stock on a 4.174-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F2 · derivative.expiration_date: The Series A Preferred Stock and Series B Preferred Stock converted into Common Stock on a 4.174-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F3 · ownership.direct: These shares are directly held by TRV II. The general partner of TRV II is Third Rock Ventures GP II, L.P. ("TRV GP II"). The general partner of TRV GP II is TRV GP II, LLC ("TRV GP II LLC"). The individual managers of TRV GP II LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of these shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
November 06, 2017 Filed Nov 6, 2017 19:04 UTC Allena Pharmaceuticals, Inc. ALNA · Entity 130904 PurchaseCommon Stock 215,000 $14.00 $3,010,000.00
Disclosure

SEC source: 0000899243-17-025454 · doc4.xml · nonDerivative · entry 2

TEPPER ROBERT I · CIK 0001192595 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,790,964

F4 · kind: Represents shares of Common Stock purchased by TRV II in the Issuer's initial public offering.

F3 · ownership.direct: These shares are directly held by TRV II. The general partner of TRV II is Third Rock Ventures GP II, L.P. ("TRV GP II"). The general partner of TRV GP II is TRV GP II, LLC ("TRV GP II LLC"). The individual managers of TRV GP II LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of these shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
November 06, 2017 Filed Nov 6, 2017 19:04 UTC Allena Pharmaceuticals, Inc. ALNA · Entity 130904 ConversionCommon Stock 2,575,964 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-17-025454 · doc4.xml · nonDerivative · entry 1

TEPPER ROBERT I · CIK 0001192595 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,575,964

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the total number of shares of Common Stock received by Third Rock Ventures II, L.P. ("TRV II") upon conversion of the Series A Preferred Stock and Series B Preferred Stock of the Issuer in connection with the closing of the Issuer's initial public offering.

F2 · price: The Series A Preferred Stock and Series B Preferred Stock converted into Common Stock on a 4.174-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F3 · ownership.direct: These shares are directly held by TRV II. The general partner of TRV II is Third Rock Ventures GP II, L.P. ("TRV GP II"). The general partner of TRV GP II is TRV GP II, LLC ("TRV GP II LLC"). The individual managers of TRV GP II LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of these shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
October 18, 2017 Filed Oct 19, 2017 16:00 UTC CytomX Therapeutics, Inc. CTMX · Entity 5124 OtherCommon Stock 1,000,000 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-17-024464 · doc4.xml · nonDerivative · entry 1

THIRD ROCK VENTURES LP · CIK 0001408591 · 10% owner

Third Rock Ventures GP, L.P. · CIK 0001578976 · 10% owner

TRV GP, LLC · CIK 0001578973 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,320,348

F1 · kind: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures, L.P. ("TRV"), TRV distributed on October 18, 2017, for no consideration, 1,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP, L.P. ("TRV GP"), the general partner of TRV, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP distributed, for no consideration, the Shares it received in the distribution by TRV to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F1 · price: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures, L.P. ("TRV"), TRV distributed on October 18, 2017, for no consideration, 1,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP, L.P. ("TRV GP"), the general partner of TRV, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP distributed, for no consideration, the Shares it received in the distribution by TRV to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F2 · ownership.direct: These shares are directly held by TRV. The general partner of TRV is TRV GP. The general partner of TRV GP is TRV GP, LLC ("TRV GP LLC"). The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
October 10, 2017 Filed Oct 11, 2017 16:00 UTC RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 ConversionSeries A-1 Junior Preferred Stock · Derivative 26,868,642 $0.00 $0.00
Disclosure

SEC source: 0000899243-17-024006 · doc4.xml · derivative · entry 3

THIRD ROCK VENTURES LP · CIK 0001408591 · 10% owner

Third Rock Ventures GP, L.P. · CIK 0001578976 · 10% owner

TRV GP, LLC · CIK 0001578973 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,930,059 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: The Series A Convertible Preferred Stock and Series A-1 Junior Preferred Stock converted into Common Stock on a 9.17-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Convertible Preferred Stock and Series A-1 Junior Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F2 · derivative.exercise_date: The Series A Convertible Preferred Stock and Series A-1 Junior Preferred Stock converted into Common Stock on a 9.17-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Convertible Preferred Stock and Series A-1 Junior Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F2 · derivative.expiration_date: The Series A Convertible Preferred Stock and Series A-1 Junior Preferred Stock converted into Common Stock on a 9.17-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Convertible Preferred Stock and Series A-1 Junior Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F3 · ownership.direct: These shares are directly held by TRV. The general partner of TRV is Third Rock Ventures GP, L.P. ("TRV GP"). The general partner of TRV GP is TRV GP, LLC ("TRV GP LLC"). The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of these shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
October 10, 2017 Filed Oct 11, 2017 16:00 UTC RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 ConversionSeries A Convertible Preferred Stock · Derivative 9,479,502 $0.00 $0.00
Disclosure

SEC source: 0000899243-17-024006 · doc4.xml · derivative · entry 2

THIRD ROCK VENTURES LP · CIK 0001408591 · 10% owner

Third Rock Ventures GP, L.P. · CIK 0001578976 · 10% owner

TRV GP, LLC · CIK 0001578973 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,033,751 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: The Series A Convertible Preferred Stock and Series A-1 Junior Preferred Stock converted into Common Stock on a 9.17-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Convertible Preferred Stock and Series A-1 Junior Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F2 · derivative.exercise_date: The Series A Convertible Preferred Stock and Series A-1 Junior Preferred Stock converted into Common Stock on a 9.17-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Convertible Preferred Stock and Series A-1 Junior Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F2 · derivative.expiration_date: The Series A Convertible Preferred Stock and Series A-1 Junior Preferred Stock converted into Common Stock on a 9.17-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Convertible Preferred Stock and Series A-1 Junior Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F3 · ownership.direct: These shares are directly held by TRV. The general partner of TRV is Third Rock Ventures GP, L.P. ("TRV GP"). The general partner of TRV GP is TRV GP, LLC ("TRV GP LLC"). The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of these shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
October 10, 2017 Filed Oct 11, 2017 16:00 UTC RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 ConversionCommon Stock 3,963,810 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-17-024006 · doc4.xml · nonDerivative · entry 1

THIRD ROCK VENTURES LP · CIK 0001408591 · 10% owner

Third Rock Ventures GP, L.P. · CIK 0001578976 · 10% owner

TRV GP, LLC · CIK 0001578973 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,981,437

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the total number of shares of Common Stock received by Third Rock Ventures, L.P. ("TRV") upon conversion of the Series A Convertible Preferred Stock and Series A-1 Junior Preferred Stock of the Issuer in connection with the closing of the Issuer's initial public offering.

F2 · price: The Series A Convertible Preferred Stock and Series A-1 Junior Preferred Stock converted into Common Stock on a 9.17-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Convertible Preferred Stock and Series A-1 Junior Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F3 · ownership.direct: These shares are directly held by TRV. The general partner of TRV is Third Rock Ventures GP, L.P. ("TRV GP"). The general partner of TRV GP is TRV GP, LLC ("TRV GP LLC"). The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of these shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
October 04, 2017 Filed Oct 4, 2017 16:09 UTC CytomX Therapeutics, Inc. CTMX · Entity 5124 SaleCommon Stock 24,777 $24.34 $603,072.18
Disclosure

SEC source: 0000899243-17-023514 · doc4.xml · nonDerivative · entry 1

TEPPER ROBERT I · CIK 0001192595 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,516

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

Read SEC document
September 28, 2017 Filed Sep 29, 2017 16:00 UTC MyoKardia, Inc. MYOK · Entity 145206 OtherCommon Stock 2,000,000 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-17-022948 · doc4.xml · nonDerivative · entry 1

Third Rock Ventures II, L.P. · CIK 0001488495 · 10% owner

Third Rock Ventures GP II, L.P. · CIK 0001614061 · 10% owner

TRV GP II, LLC · CIK 0001614073 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,885,104

F1 · kind: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures II, L.P. ("TRV II"), Third Rock Ventures GP II, L.P. ("TRV GP II") and TRV GP II, LLC ("TRV GP II LLC"), TRV II distributed on September 28, 2017, for no consideration, 2,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to TRV GP II, the general partner of TRV II, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP II distributed, for no consideration, the Shares it received in the distribution by TRV II to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F1 · price: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures II, L.P. ("TRV II"), Third Rock Ventures GP II, L.P. ("TRV GP II") and TRV GP II, LLC ("TRV GP II LLC"), TRV II distributed on September 28, 2017, for no consideration, 2,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to TRV GP II, the general partner of TRV II, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP II distributed, for no consideration, the Shares it received in the distribution by TRV II to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F2 · ownership.direct: These shares are directly held by TRV II. The general partner of TRV II is TRV GP II. The general partner of TRV GP II is TRV GP II LLC. The individual managers of TRV GP II LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
September 28, 2017 Filed Feb 13, 2018 16:00 UTC Amendment MyoKardia, Inc. MYOK · Entity 145206 OtherCommon Stock 2,000,000 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-18-003665 · doc4a.xml · nonDerivative · entry 1

Third Rock Ventures II, L.P. · CIK 0001488495 · 10% owner

Third Rock Ventures GP II, L.P. · CIK 0001614061 · 10% owner

TRV GP II, LLC · CIK 0001614073 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,885,104

F1 · kind: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures II, L.P. ("TRV II"), Third Rock Ventures GP II, L.P. ("TRV GP II") and TRV GP II, LLC ("TRV GP II LLC"), TRV II distributed on September 28, 2017, for no consideration, 2,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to TRV GP II, the general partner of TRV II, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP II distributed, for no consideration, the Shares it received in the distribution by TRV II to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F1 · price: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures II, L.P. ("TRV II"), Third Rock Ventures GP II, L.P. ("TRV GP II") and TRV GP II, LLC ("TRV GP II LLC"), TRV II distributed on September 28, 2017, for no consideration, 2,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to TRV GP II, the general partner of TRV II, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP II distributed, for no consideration, the Shares it received in the distribution by TRV II to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F2 · ownership.direct: These shares are directly held by TRV II. The general partner of TRV II is TRV GP II. The general partner of TRV GP II is TRV GP II LLC. The individual managers of TRV GP II LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
September 26, 2017 Filed Sep 27, 2017 16:01 UTC MyoKardia, Inc. MYOK · Entity 145206 SaleCommon Stock 400,000 $43.00 $17,200,000.00
Disclosure

SEC source: 0000899243-17-022639 · doc4.xml · nonDerivative · entry 2

Third Rock Ventures II, L.P. · CIK 0001488495 · 10% owner

Third Rock Ventures GP II, L.P. · CIK 0001614061 · 10% owner

TRV GP II, LLC · CIK 0001614073 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,885,104

F1 · ownership.direct: These shares are directly held by Third Rock Ventures II, L.P. ("TRV II"). The general partner of TRV II is Third Rock Ventures GP II, L.P. ("TRV GP II"). The general partner of TRV GP II is TRV GP II, LLC ("TRV GP II LLC"). The individual managers of TRV GP II LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
September 25, 2017 Filed Sep 27, 2017 16:01 UTC MyoKardia, Inc. MYOK · Entity 145206 SaleCommon Stock 201,400 $43.00 $8,660,200.00
Disclosure

SEC source: 0000899243-17-022639 · doc4.xml · nonDerivative · entry 1

Third Rock Ventures II, L.P. · CIK 0001488495 · 10% owner

Third Rock Ventures GP II, L.P. · CIK 0001614061 · 10% owner

TRV GP II, LLC · CIK 0001614073 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,285,104

F1 · ownership.direct: These shares are directly held by Third Rock Ventures II, L.P. ("TRV II"). The general partner of TRV II is Third Rock Ventures GP II, L.P. ("TRV GP II"). The general partner of TRV GP II is TRV GP II, LLC ("TRV GP II LLC"). The individual managers of TRV GP II LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
September 19, 2017 Filed Sep 21, 2017 16:00 UTC CytomX Therapeutics, Inc. CTMX · Entity 5124 SaleCommon Stock 20,000 $18.00 $360,000.00
Disclosure

SEC source: 0000899243-17-022406 · doc4.xml · nonDerivative · entry 1

TEPPER ROBERT I · CIK 0001192595 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,293

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

Read SEC document
September 11, 2017 Filed Sep 12, 2017 16:05 UTC MyoKardia, Inc. MYOK · Entity 145206 SaleCommon Stock 20,000 $44.25 $885,080.00
Disclosure

SEC source: 0000899243-17-021893 · doc4.xml · nonDerivative · entry 3

Third Rock Ventures II, L.P. · CIK 0001488495 · 10% owner

Third Rock Ventures GP II, L.P. · CIK 0001614061 · 10% owner

TRV GP II, LLC · CIK 0001614073 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,651

F3 · kind: Sale executed by Tepper.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.05 to $44.425, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4).

F5 · balance_after: Third Rock Ventures III, L.P. ("TRV III") directly holds 1,496,598 shares of Common Stock of the Issuer. The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Levin, Starr and Tepper. Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F5 · ownership.direct: Third Rock Ventures III, L.P. ("TRV III") directly holds 1,496,598 shares of Common Stock of the Issuer. The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Levin, Starr and Tepper. Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

F6 · ownership.direct: The shares are directly held by Tepper.

Read SEC document
September 08, 2017 Filed Sep 12, 2017 16:05 UTC MyoKardia, Inc. MYOK · Entity 145206 SaleCommon Stock 900 $42.39 $38,149.20
Disclosure

SEC source: 0000899243-17-021893 · doc4.xml · nonDerivative · entry 2

Third Rock Ventures II, L.P. · CIK 0001488495 · 10% owner

Third Rock Ventures GP II, L.P. · CIK 0001614061 · 10% owner

TRV GP II, LLC · CIK 0001614073 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,486,504

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.20 to $42.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2).

F1 · ownership.direct: These shares are directly held by Third Rock Ventures II, L.P. ("TRV II"). The general partner of TRV II is Third Rock Ventures GP II, L.P. ("TRV GP II"). The general partner of TRV GP II is TRV GP II, LLC ("TRV GP II LLC"). The individual managers of TRV GP II LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
September 08, 2017 Filed Sep 12, 2017 16:05 UTC MyoKardia, Inc. MYOK · Entity 145206 SaleCommon Stock 200,350 $41.00 $8,214,350.00
Disclosure

SEC source: 0000899243-17-021893 · doc4.xml · nonDerivative · entry 1

Third Rock Ventures II, L.P. · CIK 0001488495 · 10% owner

Third Rock Ventures GP II, L.P. · CIK 0001614061 · 10% owner

TRV GP II, LLC · CIK 0001614073 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,487,404

F1 · ownership.direct: These shares are directly held by Third Rock Ventures II, L.P. ("TRV II"). The general partner of TRV II is Third Rock Ventures GP II, L.P. ("TRV GP II"). The general partner of TRV GP II is TRV GP II, LLC ("TRV GP II LLC"). The individual managers of TRV GP II LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
July 25, 2017 Filed Jul 26, 2017 20:30 UTC KALA BIO, Inc. KALA · Entity 7964 ConversionCommon Stock Warrant (right to buy) · Derivative 33,333 $0.00 Strike: $7.50 $0.00
Disclosure

SEC source: 0001179110-17-010702 · edgar.xml · derivative · entry 6

TEPPER ROBERT I · CIK 0001192595 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote.

Disclosed balance after: 33,333

Underlying: Common Stock · 33,333 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The Series B Preferred Stock Warrant was exercisable for such shares of Preferred Stock at an exercise price of $1.44 per share. Upon the closing of the Issuer's initial public offering, the Warrant automatically became exercisable for 33,333 shares of Common Stock at an exercise price of $7.50 per share. The Warrant is exercisable at any time at the holder's election on or before April 16, 2021.

F2 · derivative.expiration_date: The Series B Preferred Stock Warrant was exercisable for such shares of Preferred Stock at an exercise price of $1.44 per share. Upon the closing of the Issuer's initial public offering, the Warrant automatically became exercisable for 33,333 shares of Common Stock at an exercise price of $7.50 per share. The Warrant is exercisable at any time at the holder's election on or before April 16, 2021.

F4 · ownership.nature: These shares are held by TRV. The general partner of TRV is TRV GP. The general partner of TRV GP is TRV GP LLC. The individual managers of TRV GP LLC are Levin, Starr and Tepper. Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
July 25, 2017 Filed Jul 26, 2017 20:30 UTC KALA BIO, Inc. KALA · Entity 7964 ConversionSeries B Preferred Stock Warrant (right to buy) · Derivative 173,611 $0.00 $0.00
Disclosure

SEC source: 0001179110-17-010702 · edgar.xml · derivative · entry 5

TEPPER ROBERT I · CIK 0001192595 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote.

Disclosed balance after: 0

Underlying: Series B Preferred Stock · 173,611 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: The Series B Preferred Stock Warrant was exercisable for such shares of Preferred Stock at an exercise price of $1.44 per share. Upon the closing of the Issuer's initial public offering, the Warrant automatically became exercisable for 33,333 shares of Common Stock at an exercise price of $7.50 per share. The Warrant is exercisable at any time at the holder's election on or before April 16, 2021.

F2 · shares: The Series B Preferred Stock Warrant was exercisable for such shares of Preferred Stock at an exercise price of $1.44 per share. Upon the closing of the Issuer's initial public offering, the Warrant automatically became exercisable for 33,333 shares of Common Stock at an exercise price of $7.50 per share. The Warrant is exercisable at any time at the holder's election on or before April 16, 2021.

F2 · derivative.exercise_date: The Series B Preferred Stock Warrant was exercisable for such shares of Preferred Stock at an exercise price of $1.44 per share. Upon the closing of the Issuer's initial public offering, the Warrant automatically became exercisable for 33,333 shares of Common Stock at an exercise price of $7.50 per share. The Warrant is exercisable at any time at the holder's election on or before April 16, 2021.

F2 · derivative.expiration_date: The Series B Preferred Stock Warrant was exercisable for such shares of Preferred Stock at an exercise price of $1.44 per share. Upon the closing of the Issuer's initial public offering, the Warrant automatically became exercisable for 33,333 shares of Common Stock at an exercise price of $7.50 per share. The Warrant is exercisable at any time at the holder's election on or before April 16, 2021.

F2 · derivative.underlying_shares: The Series B Preferred Stock Warrant was exercisable for such shares of Preferred Stock at an exercise price of $1.44 per share. Upon the closing of the Issuer's initial public offering, the Warrant automatically became exercisable for 33,333 shares of Common Stock at an exercise price of $7.50 per share. The Warrant is exercisable at any time at the holder's election on or before April 16, 2021.

F2 · balance_after: The Series B Preferred Stock Warrant was exercisable for such shares of Preferred Stock at an exercise price of $1.44 per share. Upon the closing of the Issuer's initial public offering, the Warrant automatically became exercisable for 33,333 shares of Common Stock at an exercise price of $7.50 per share. The Warrant is exercisable at any time at the holder's election on or before April 16, 2021.

F3 · ownership.nature: These shares were held by Third Rock Ventures, L.P. ("TRV"). The general partner of TRV is Third Rock Ventures GP, L.P. ("TRV GP"). The general partner of TRV GP is TRV GP, LLC ("TRV GP LLC"). The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
July 25, 2017 Filed Jul 26, 2017 20:30 UTC KALA BIO, Inc. KALA · Entity 7964 ConversionSeries B Preferred Stock · Derivative 2,265,764 $0.00 $0.00
Disclosure

SEC source: 0001179110-17-010702 · edgar.xml · derivative · entry 4

TEPPER ROBERT I · CIK 0001192595 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote.

Disclosed balance after: 0

Underlying: Common Stock · 435,029 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock converted into Common Stock on a 5.2083-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F1 · derivative.exercise_date: The Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock converted into Common Stock on a 5.2083-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F1 · derivative.expiration_date: The Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock converted into Common Stock on a 5.2083-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F3 · ownership.nature: These shares were held by Third Rock Ventures, L.P. ("TRV"). The general partner of TRV is Third Rock Ventures GP, L.P. ("TRV GP"). The general partner of TRV GP is TRV GP, LLC ("TRV GP LLC"). The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
July 25, 2017 Filed Jul 26, 2017 20:30 UTC KALA BIO, Inc. KALA · Entity 7964 ConversionSeries A Preferred Stock · Derivative 2,500,000 $0.00 $0.00
Disclosure

SEC source: 0001179110-17-010702 · edgar.xml · derivative · entry 3

TEPPER ROBERT I · CIK 0001192595 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote.

Disclosed balance after: 0

Underlying: Common Stock · 480,003 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock converted into Common Stock on a 5.2083-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F1 · derivative.exercise_date: The Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock converted into Common Stock on a 5.2083-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F1 · derivative.expiration_date: The Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock converted into Common Stock on a 5.2083-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F3 · ownership.nature: These shares were held by Third Rock Ventures, L.P. ("TRV"). The general partner of TRV is Third Rock Ventures GP, L.P. ("TRV GP"). The general partner of TRV GP is TRV GP, LLC ("TRV GP LLC"). The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
July 25, 2017 Filed Jul 26, 2017 20:30 UTC KALA BIO, Inc. KALA · Entity 7964 ConversionSeries Seed Preferred Stock · Derivative 3,677,374 $0.00 $0.00
Disclosure

SEC source: 0001179110-17-010702 · edgar.xml · derivative · entry 2

TEPPER ROBERT I · CIK 0001192595 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote.

Disclosed balance after: 0

Underlying: Common Stock · 706,060 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock converted into Common Stock on a 5.2083-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F1 · derivative.exercise_date: The Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock converted into Common Stock on a 5.2083-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F1 · derivative.expiration_date: The Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock converted into Common Stock on a 5.2083-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F3 · ownership.nature: These shares were held by Third Rock Ventures, L.P. ("TRV"). The general partner of TRV is Third Rock Ventures GP, L.P. ("TRV GP"). The general partner of TRV GP is TRV GP, LLC ("TRV GP LLC"). The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
July 25, 2017 Filed Jul 26, 2017 20:30 UTC KALA BIO, Inc. KALA · Entity 7964 ConversionCommon Stock 1,621,092 Not disclosed Not disclosed
Disclosure

SEC source: 0001179110-17-010702 · edgar.xml · nonDerivative · entry 1

TEPPER ROBERT I · CIK 0001192595 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote.

Disclosed balance after: 1,621,092

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock converted into Common Stock on a 5.2083-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F4 · ownership.nature: These shares are held by TRV. The general partner of TRV is TRV GP. The general partner of TRV GP is TRV GP LLC. The individual managers of TRV GP LLC are Levin, Starr and Tepper. Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
July 19, 2017 Filed Jul 21, 2017 20:21 UTC KALA BIO, Inc. KALA · Entity 7964 GrantStock Option (right to buy) · Derivative 12,960 $0.00 Strike: $15.00 $0.00
Disclosure

SEC source: 0001179110-17-010597 · edgar.xml · derivative · entry 1

TEPPER ROBERT I · CIK 0001192595 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,960

Underlying: Common Stock · 12,960 shares

Expires 2027-07-18

F1 · derivative.exercise_date: This option was granted, effective on July 19, 2017 and vests over one year, with 8.33% of the shares underlying the option vesting on August 19, 2017, and an addition 8.33% of the shares underlying the option vesting at the end of each successive one-month period thereafter.

Read SEC document
July 13, 2017 Filed Jul 13, 2017 20:07 UTC CytomX Therapeutics, Inc. CTMX · Entity 5124 OtherCommon Stock 850,000 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-17-018238 · doc4.xml · nonDerivative · entry 1

THIRD ROCK VENTURES LP · CIK 0001408591 · 10% owner

Third Rock Ventures GP, L.P. · CIK 0001578976 · 10% owner

TRV GP, LLC · CIK 0001578973 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,320,348

F1 · kind: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures, L.P. ("TRV"), TRV distributed on July 13, 2017, for no consideration, 850,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP, L.P. ("TRV GP"), the general partner of TRV, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP distributed, for no consideration, the Shares it received in the distribution by TRV to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F1 · price: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures, L.P. ("TRV"), TRV distributed on July 13, 2017, for no consideration, 850,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP, L.P. ("TRV GP"), the general partner of TRV, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP distributed, for no consideration, the Shares it received in the distribution by TRV to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F2 · ownership.direct: These shares are directly held by TRV. The general partner of TRV is TRV GP. The general partner of TRV GP is TRV GP, LLC ("TRV GP LLC"). The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
June 29, 2017 Filed Jun 30, 2017 16:00 UTC CytomX Therapeutics, Inc. CTMX · Entity 5124 SaleCommon Stock 15,000 $16.00 $240,000.00
Disclosure

SEC source: 0000899243-17-017617 · doc4.xml · nonDerivative · entry 1

TEPPER ROBERT I · CIK 0001192595 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,777

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

Read SEC document
June 14, 2017 Filed Jun 16, 2017 16:05 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 OtherCommon Stock 1,000,000 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-17-016554 · doc4.xml · nonDerivative · entry 1

Third Rock Ventures II, L.P. · CIK 0001488495 · 10% owner

Third Rock Ventures GP II, L.P. · CIK 0001614061 · 10% owner

TRV GP II, LLC · CIK 0001614073 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,475,191

F1 · kind: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures II, L.P. ("TRV II"), Third Rock Ventures GP II, L.P. ("TRV GP II") and TRV GP II, LLC ("TRV GP II LLC"), TRV II distributed on June 14, 2017, for no consideration, 1,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to TRV GP II, the general partner of TRV II, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP II distributed, for no consideration, the Shares it received in the distribution by TRV II to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F1 · price: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures II, L.P. ("TRV II"), Third Rock Ventures GP II, L.P. ("TRV GP II") and TRV GP II, LLC ("TRV GP II LLC"), TRV II distributed on June 14, 2017, for no consideration, 1,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to TRV GP II, the general partner of TRV II, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP II distributed, for no consideration, the Shares it received in the distribution by TRV II to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F2 · ownership.direct: These shares are directly held by TRV II. The general partner of TRV II is TRV GP II. The general partner of TRV GP II is TRV GP II LLC. The individual managers of TRV GP II LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
May 17, 2017 Filed May 19, 2017 16:14 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 OtherCommon Stock 1,000,000 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-17-013908 · doc4.xml · nonDerivative · entry 3

Third Rock Ventures II, L.P. · CIK 0001488495 · 10% owner

Third Rock Ventures GP II, L.P. · CIK 0001614061 · 10% owner

TRV GP II, LLC · CIK 0001614073 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,475,191

F1 · kind: Reflects gifts by Mark Levin ("Levin"). The remaining shares are directly held by Levin.

F2 · price: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures II, L.P. ("TRV II"), Third Rock Ventures GP II, L.P. ("TRV GP II") and TRV GP II, LLC ("TRV GP II LLC"), TRV II distributed on May 17, 2017, for no consideration, 1,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to TRV GP II, the general partner of TRV II, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP II distributed, for no consideration, the Shares it received in the distribution by TRV II to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F3 · ownership.direct: These shares are directly held by TRV II. The general partner of TRV II is TRV GP II. The general partner of TRV GP II is TRV GP II LLC. The individual managers of TRV GP II LLC are Levin, Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
April 18, 2017 Filed May 19, 2017 16:14 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 GiftCommon Stock 1,708 $0.00 $0.00
Disclosure

SEC source: 0000899243-17-013908 · doc4.xml · nonDerivative · entry 2

Third Rock Ventures II, L.P. · CIK 0001488495 · 10% owner

Third Rock Ventures GP II, L.P. · CIK 0001614061 · 10% owner

TRV GP II, LLC · CIK 0001614073 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 163,996

F1 · shares: Reflects gifts by Mark Levin ("Levin"). The remaining shares are directly held by Levin.

F1 · ownership.direct: Reflects gifts by Mark Levin ("Levin"). The remaining shares are directly held by Levin.

Read SEC document
April 12, 2017 Filed Apr 14, 2017 20:00 UTC Voyager Therapeutics, Inc. VYGR · Entity 6271 OtherCommon Stock 920,000 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-17-010312 · doc4.xml · nonDerivative · entry 1

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,391,176

F1 · kind: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures III, L.P. ("TRV III"), Third Rock Ventures GP III, L.P. ("TRV GP III") and TRV GP III, LLC ("TRV GP III LLC"), TRV III distributed on April 12, 2017, for no consideration, 920,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to TRV GP III, the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F1 · price: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures III, L.P. ("TRV III"), Third Rock Ventures GP III, L.P. ("TRV GP III") and TRV GP III, LLC ("TRV GP III LLC"), TRV III distributed on April 12, 2017, for no consideration, 920,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to TRV GP III, the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F2 · ownership.direct: These shares are directly held by TRV III. The general partner of TRV III is TRV GP III. The general partner of TRV GP III is TRV GP III LLC. The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
April 11, 2017 Filed May 19, 2017 16:14 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 GiftCommon Stock 50,000 $0.00 $0.00
Disclosure

SEC source: 0000899243-17-013908 · doc4.xml · nonDerivative · entry 1

Third Rock Ventures II, L.P. · CIK 0001488495 · 10% owner

Third Rock Ventures GP II, L.P. · CIK 0001614061 · 10% owner

TRV GP II, LLC · CIK 0001614073 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 165,704

F1 · shares: Reflects gifts by Mark Levin ("Levin"). The remaining shares are directly held by Levin.

F1 · ownership.direct: Reflects gifts by Mark Levin ("Levin"). The remaining shares are directly held by Levin.

Read SEC document
April 06, 2017 Filed Apr 6, 2017 16:00 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 OtherCommon Stock 2,000,000 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-17-009646 · doc4.xml · nonDerivative · entry 1

Third Rock Ventures II, L.P. · CIK 0001488495 · 10% owner

Third Rock Ventures GP II, L.P. · CIK 0001614061 · 10% owner

TRV GP II, LLC · CIK 0001614073 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,475,191

F1 · kind: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures II, L.P. ("TRV II"), Third Rock Ventures GP II, L.P. ("TRV GP II") and TRV GP II, LLC ("TRV GP II LLC"), TRV II distributed on April 6, 2017, for no consideration, 2,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to TRV GP II, the general partner of TRV II, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP II distributed, for no consideration, the Shares it received in the distribution by TRV II to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F1 · price: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures II, L.P. ("TRV II"), Third Rock Ventures GP II, L.P. ("TRV GP II") and TRV GP II, LLC ("TRV GP II LLC"), TRV II distributed on April 6, 2017, for no consideration, 2,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to TRV GP II, the general partner of TRV II, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP II distributed, for no consideration, the Shares it received in the distribution by TRV II to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F2 · ownership.direct: These shares are directly held by TRV II. The general partner of TRV II is TRV GP II. The general partner of TRV GP II is TRV GP II LLC. The individual managers of TRV GP II LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
April 06, 2017 Filed Apr 10, 2017 17:30 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 SaleCommon Stock 31,225 $33.23 $1,037,575.53
Disclosure

SEC source: 0000899243-17-009893 · doc4.xml · nonDerivative · entry 1

TEPPER ROBERT I · CIK 0001192595 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 229,773

F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1).

Read SEC document
March 30, 2017 Filed Apr 3, 2017 16:01 UTC MyoKardia, Inc. MYOK · Entity 145206 OtherCommon Stock 850,000 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-17-009104 · doc4.xml · nonDerivative · entry 1

Third Rock Ventures II, L.P. · CIK 0001488495 · 10% owner

Third Rock Ventures GP II, L.P. · CIK 0001614061 · 10% owner

TRV GP II, LLC · CIK 0001614073 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,687,754

F1 · kind: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures II, L.P. ("TRV II"), Third Rock Ventures GP II, L.P. ("TRV GP II") and TRV GP II, LLC ("TRV GP II LLC"), TRV II distributed on March 30, 2017, for no consideration, 850,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to TRV GP II, the general partner of TRV II, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP II distributed, for no consideration, the Shares it received in the distribution by TRV II to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F1 · price: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures II, L.P. ("TRV II"), Third Rock Ventures GP II, L.P. ("TRV GP II") and TRV GP II, LLC ("TRV GP II LLC"), TRV II distributed on March 30, 2017, for no consideration, 850,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to TRV GP II, the general partner of TRV II, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP II distributed, for no consideration, the Shares it received in the distribution by TRV II to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F2 · ownership.direct: These shares are directly held by TRV II. The general partner of TRV II is TRV GP II. The general partner of TRV GP II is TRV GP II LLC. The individual managers of TRV GP II LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
March 27, 2017 Filed Mar 27, 2017 19:28 UTC CytomX Therapeutics, Inc. CTMX · Entity 5124 SaleCommon Stock 650,000 $18.00 $11,700,195.00
Disclosure

SEC source: 0000899243-17-008731 · doc4.xml · nonDerivative · entry 2

THIRD ROCK VENTURES LP · CIK 0001408591 · 10% owner

Third Rock Ventures GP, L.P. · CIK 0001578976 · 10% owner

TRV GP, LLC · CIK 0001578973 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,170,348

F2 · price: This price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.45, inclusive. Each of the reporting persons undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2).

F1 · ownership.direct: These shares are directly held by Third Rock Ventures, L.P. ("TRV"). The general partner of TRV is Third Rock Ventures GP, L.P. ("TRV GP"). The general partner of TRV GP is TRV GP, LLC ("TRV GP LLC"). The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
March 23, 2017 Filed Mar 27, 2017 19:28 UTC CytomX Therapeutics, Inc. CTMX · Entity 5124 SaleCommon Stock 1,000,000 $17.00 $17,000,200.00
Disclosure

SEC source: 0000899243-17-008731 · doc4.xml · nonDerivative · entry 1

THIRD ROCK VENTURES LP · CIK 0001408591 · 10% owner

Third Rock Ventures GP, L.P. · CIK 0001578976 · 10% owner

TRV GP, LLC · CIK 0001578973 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,820,348

F1 · ownership.direct: These shares are directly held by Third Rock Ventures, L.P. ("TRV"). The general partner of TRV is Third Rock Ventures GP, L.P. ("TRV GP"). The general partner of TRV GP is TRV GP, LLC ("TRV GP LLC"). The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
March 15, 2017 Filed Mar 16, 2017 17:30 UTC CytomX Therapeutics, Inc. CTMX · Entity 5124 OtherCommon Stock 850,000 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-17-007785 · doc4.xml · nonDerivative · entry 1

THIRD ROCK VENTURES LP · CIK 0001408591 · 10% owner

Third Rock Ventures GP, L.P. · CIK 0001578976 · 10% owner

TRV GP, LLC · CIK 0001578973 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,820,348

F1 · kind: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures, L.P. ("TRV"), TRV distributed on March 15, 2017, for no consideration, 850,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP, L.P. ("TRV GP"), the general partner of TRV, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP distributed, for no consideration, the Shares it received in the distribution by TRV to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F1 · price: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures, L.P. ("TRV"), TRV distributed on March 15, 2017, for no consideration, 850,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP, L.P. ("TRV GP"), the general partner of TRV, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP distributed, for no consideration, the Shares it received in the distribution by TRV to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F2 · ownership.direct: These shares are directly held by TRV. The general partner of TRV is TRV GP. The general partner of TRV GP is TRV GP, LLC ("TRV GP LLC"). The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document
March 02, 2017 Filed Mar 6, 2017 19:47 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 SaleCommon Stock 10,900 $28.73 $313,146.10
Disclosure

SEC source: 0000899243-17-006623 · doc4.xml · nonDerivative · entry 5

Third Rock Ventures II, L.P. · CIK 0001488495 · 10% owner

Third Rock Ventures GP II, L.P. · CIK 0001614061 · 10% owner

TRV GP II, LLC · CIK 0001614073 · 10% owner

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 146,208

F6 · price: This price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.50 to $28.975, inclusive.

F4 · ownership.direct: These shares are directly held by Levin.

Read SEC document
March 02, 2017 Filed Mar 6, 2017 19:47 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 SaleCommon Stock 7,279 $27.69 $201,526.39
Disclosure

SEC source: 0000899243-17-006623 · doc4.xml · nonDerivative · entry 4

Third Rock Ventures II, L.P. · CIK 0001488495 · 10% owner

Third Rock Ventures GP II, L.P. · CIK 0001614061 · 10% owner

TRV GP II, LLC · CIK 0001614073 · 10% owner

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 157,108

F5 · price: This price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.35 to $28.275, inclusive.

F4 · ownership.direct: These shares are directly held by Levin.

Read SEC document
March 02, 2017 Filed Mar 6, 2017 19:47 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 SaleCommon Stock 27,115 $26.95 $730,803.48
Disclosure

SEC source: 0000899243-17-006623 · doc4.xml · nonDerivative · entry 3

Third Rock Ventures II, L.P. · CIK 0001488495 · 10% owner

Third Rock Ventures GP II, L.P. · CIK 0001614061 · 10% owner

TRV GP II, LLC · CIK 0001614073 · 10% owner

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 164,387

F3 · price: This price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.35 to $27.30, inclusive. Levin undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3), (5) and (6) to this Form 4.

F4 · ownership.direct: These shares are directly held by Levin.

Read SEC document
March 02, 2017 Filed Mar 6, 2017 19:47 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 SaleCommon Stock 1,000,000 $25.50 $25,500,000.00
Disclosure

SEC source: 0000899243-17-006623 · doc4.xml · nonDerivative · entry 2

Third Rock Ventures II, L.P. · CIK 0001488495 · 10% owner

Third Rock Ventures GP II, L.P. · CIK 0001614061 · 10% owner

TRV GP II, LLC · CIK 0001614073 · 10% owner

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

LEVIN MARK J · CIK 0001180428 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 285,713

F2 · ownership.direct: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Levin, Starr and Tepper. Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.